Iconovo specializes in the development of inhalation products, including inhaler devices and dry powder formulations. The company operates in the pharmaceutical and medical device market, serving clients such as pharmaceutical companies and research institutions. Iconovo's business model revolves around offering a comprehensive service package that includes device design, formulation development, analytical testing, and documentation. The company generates revenue through service contracts, development agreements, and licensing deals. Iconovo's unique combination of engineering and pharmaceutical expertise allows it to shorten the time to product launch and reduce project risks and development costs. The company has built state-of-the-art laboratories for the analysis, development, and characterization of powder formulations. Recently, Iconovo has been involved in the development of a nasal COVID-19 vaccine, showcasing its capabilities in addressing urgent healthcare needs.

Keywords: inhalation products, inhaler devices, dry powder formulations, pharmaceutical expertise, medical devices, development agreements, licensing deals, analytical testing, COVID-19 vaccine, state-of-the-art laboratories.